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ABSTRACT
Introduction: Penile cancer (PeCa) is an orphan
disease in European countries. The current
guidelines are predominantly based on retro-
spective studies with a low level of evidence. In
our study, we aimed to identify predictors for
guideline-conform treatment and hypothesize
that reference centers for PeCa and physicians’
experience promote guideline compliance and
therefore correct local tumor therapy.
Methods: This study is part of the European
PROspective Penile Cancer Study (E-PROPS), an
international collaboration group evaluating
therapeutic management for PeCa in Central
Europe. For this module, a 14-item-survey was
developed and sent to 681 urologists in 45
European centers. Three questions focused on
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therapeutic decisions for PeCa in clinical stage
Tis, Ta-T1a, and T1b. Four questions addressed
potential personal confounders. Survey results
were analyzed by bootstrap-adjusted stepwise
multivariate linear regression analysis to iden-
tify predictors for EAU guideline-conform local
treatment of PeCa.
Results: For local therapy of cTis 80.4% rec-
ommended guideline-conform treatment, for
cTa-cT1a 87.3% and for cT1b 59.1%. In total,
42.4% chose a correct approach in all tumor
stages. The number of PeCa patients treated at
the hospital, a higher level of training of the
physicians, resource-based answering and the
option of penile-sparing surgery offered at the
hospital matched with giving guideline-con-
form recommendations and thus accurate local
tumor treatment.
Conclusion: Patients with PeCa are best treated
by experienced physicians, in centers with a
high number of cases, which also offer a wide
range of local tumor therapy. This could be
offered in reference centers.
Keywords: E-PROPS; Guideline adherence;
Local tumor treatment; Penile cancer;
Reference centers
Key Summary Points
Why carry out this study?
Penile cancer is an orphan disease, and
guidelines are predominantly based on
retrospective studies with a low level of
evidence. Recent studies have shown low
guideline compliance.
We aimed to identify predictors for
guideline-conform treatment
recommendations and hypothesize that
the establishment of reference centers and
physicians’ experience promote guideline-
conform local tumor therapy.
What was learned from the study?
Guideline-conform treatment
recommendations were dependent on
tumor stage and the number of PeCa
patients treated at the hospital, a higher
level of training of the physicians,
resource-based answering and the option
of penile-sparing surgery offered at the
hospital.
This could be offered in reference centers.
DIGITAL FEATURES
This article is published with digital features,
including a summary slide, to facilitate under-
standing of the article. To view digital features
for this article go to https://doi.org/10.6084/
m9.figshare.12982370.
INTRODUCTION
Penile cancer (PeCa) is an orphan disease with a
low incidence rate in European countries of
0.45–1.7 per 100,000 male inhabitants [1]. The
European Association of Urology (EAU) guide-
lines on PeCa represent the current standard
treatment recommendations [2]. Due to the low
number of cases and therefore lack of treatment
experience, high-level evidence to back up these
guidelines is scarce [3]. Surgical local therapy for
primary lesions depends strictly on tumor stage
and ranges from local excision over glansec-
tomy to partial or radical penectomy. Penile-
sparing surgery is defined as complete preser-
vation of the corpora cavernosa of the penis and
is used as an established proxy for the quality of
therapy in local tumor stages up to cT2 [4]. A
carefully considered balance of complete tumor
removal and maximal tissue preservation is
essential for successful and guideline-conform
treatment. The extent of resection after radical
surgeries has been shown to inversely correlate
with the postoperative quality of life, i.e., the
more radical the surgery, the less preserved
organ function is achieved, resulting in lower
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quality of life [5]. Former recommendations of
wide tumor-negative surgical margins of up to
20 mm have been replaced by organ-sparing
strategies, reducing radicality to a minimum of
margins as narrow as 1 mm [6]. In summary,
treatment of PeCa should be as organ-sparing as
possible, while as radical as necessary. Despite
higher recurrence rates after organ-preserving
treatment, no impact on overall survival was
observed [7].
A recently published retrospective multi-
center study demonstrated that only 66% of
patients received local tumor therapy that
complied with the recommendations of the
2009 EAU guidelines on PeCa [8]. In one-third
of the patients who did not receive correct local
tumor therapy, this was due to surgeons’ pref-
erence. In the majority of cases, this led to a
more aggressive therapeutic approach [8]. This
observation coincides with data of the Swedish
national PeCa register. The authors showed that
guideline adherence is as low as 71% for
patients where organ-sparing treatment is indi-
cated [9].
The discrepancy between guideline and real-
live treatment recommendations for local
tumor treatment is addressed by this study.
Through a survey that was distributed between
681 urologists in Central Europe, we aimed to
identify variables that predict guideline-com-
pliant local tumor treatment. We assume that
further specialization of the clinic and more
experience of the physician promote guideline
compliance and therefore correct local tumor
therapy.
METHODS
The European PROspective Penile Cancer Study
(E-PROPS) was initiated to evaluate the thera-
peutic management of PeCa patients. The study
consists of three separate modules, which are
carried out in consecutive order. This article is
part of the first module. Its centerpiece is a
standardized survey aiming to assess the current
state of treatment. The second module will be a
retrospective multicenter study about the
treatment PeCa patients received over the last
10 years. The third and final module will
represent a prospective multicenter study
including a tissue and serum database. The
survey of E-PROPS module 1 was sent to 681
urologists working in 45 centers participating in
E-PROPS (Germany n = 34, Austria n = 8,
Switzerland n = 2, Italy n = 1). The survey was
developed by the E-PROPS steering committee.
It is written in German, an official language in
all participating countries, and was checked for
comprehensibility prior to its distribution. It
consists of 14 questions assessing (1) the posi-
tion of the surveyed person in the urological
clinic, (2) personal responsibilities in PeCa
therapy management, (3) individual knowledge
on penile PeCa, (4) information about clinic-
specific workflow, (5) the therapeutic manage-
ment of PeCa patients (primary surgery, lym-
phadenectomy, chemotherapy) in the
participating urological department and (6) the
need for additional help to answer the ques-
tionnaire. Information about the participating
physicians is given in Table 1.
Additionally, the following center-related
information was collected: (1) the level of
medical care (general hospital vs. advanced care
hospital vs. maximum care hospital vs. univer-
sity hospital) and its academic status (university
vs. non-university), (2) the size of the urological
department (number of practicing doctors—
residents and specialists; number of beds for
inpatient care), (3) the exact number of PeCa
patients who received surgical treatment in the
urological department in 2017, (4) availability
and workflow for certain PeCa treatment regi-
mens (radiotherapy is available at the hospital
to treat PeCa: yes or no; chemotherapy is
administered by urologists or medical oncolo-
gists or both), (5) the extent of surgical therapy
offered to PeCa patients (laser therapy: yes or
no; penile-sparing surgery: yes or no). All
information about the participating centers that
is of interest for this part of the E-PROPS project
is given in Table 2.
The survey, its application and the recruit-
ment letter were submitted to the Institutional
Review Board at the University of Regensburg,
and the project was granted exempt status. The
IRB declared that as a survey study for physi-
cians, obtaining information on treatment rec-
ommendations for hypothetical patient cases,
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no written consent is needed and therefore can
be waived. This study was conducted in accor-
dance with the Declaration of Helsinki in its
latest version. The survey did not provide any
information about the person completing it,
assuring the anonymization of the data. The
physicians in every participating medical center
were informed about the study and its purpose
and agreed that their survey data were being
used as part of the study. The survey was dis-
tributed in the third quarter of 2018.
This article deals with the state of the art of
local tumor therapy and its coherence with
guideline recommendations. Participants in the
survey were asked about the local tumor treat-
ment patients will most likely receive at their
institution for PeCa stage cTis (1), cTa and cT1a
(2) or cT1b (3) (Table 3). For each tumor stage,
several therapeutic regimes were given. How-
ever, not all of them complied with the EAU
guidelines [2]. Participants also had the oppor-
tunity to indicate that they do not know the
correct answer. The exact wording of the survey
is found in Table 3 (the questions have been
translated from German to English; the correct
answers are written in bold).
Twelve independent variables with possible
influence on treatment decisions were defined
in advance. They are listed in Table 4. They are
either related to the participant or the partici-
pating center. All independent variables were
evaluated for their influence on guideline
compliance. This was carried out by examining
the relationship between the independent
variables and the number of correctly answered
questions (0–3), which we defined as the com-
posite endpoint. The endpoint represents a
scale for guideline adherence, where 0 correct
answers corresponds to poor and 3 correct
answers to exceptional guideline compliance.
Testing was done by multivariate linear regres-
sion analysis (stepwise approach). The internal
validity of the model was evaluated by boot-
strapping with 1000 re-samples. The regression
coefficient B and the p value were calculated for
all independent variables. Regression coeffi-
cients[0 indicate a positive influence of the
Table 1 Information on participating physicians
Criterion n (%)
Professional status 554 (100%)
Resident 241 (43.5%)
Board-certified urologist 107 (19.3%)
Leading position (senior physician or head of the department) 206 (37.2%)
Independently performs surgery for penile carcinoma 556 (100%)
Yes 247 (44.4%)
No 309 (55.6%)
Knows actual HPV incidence for penile carcinoma 554 (100%)
Yes 344 (62.1%)
No 210 (37.9%)
Use of any additional source of reference to answer the survey 549 (100%)
Yes 128 (23.3%)
No 421 (76.7%)
This table gives detailed information on the participating physicians. The information was obtained by the E-PROPS study
group survey and given in total numbers and percentages in relation to the total number of participants
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independent variable on the number of cor-
rectly answered questions.
The type I error was not adjusted for multiple
testing. Therefore, the results of inferential
statistics are descriptive only. Statistical analysis
was performed using the open-source R statis-
tical software package, version 3.5.1 (The R
Foundation for Statistical Computing, Vienna,
Austria).
RESULTS
Five hundred sixty-six out of 681 urologists
returned their completed survey. Nine ques-
tionnaires were excluded, as they did not meet
the minimum requirement for completeness
(13/14 questions answered = 92.0%). In total,
we included 557 questionnaires for further sta-
tistical investigation [response rate (RR) 85.7%,
interquartile range (IQR) 75–94; calculated as
the median of the individual response rate of
the 45 participating clinics].
The number of guideline-conform treatment
recommendations given by the participants for
the respective tumor stage is listed in Table 5.
For local therapy of PeCa Tis, 80.4% chose a
therapeutic approach recommended by the EAU
guidelines (topical therapy 8.4%; laser therapy
49.4%; glans resurfacing 22.6%); 9.4% chose an
approach not recommended by the EAU
guidelines (partial penectomy 8.6%; radiother-
apy 0.8%), and 10.2% declared not to know the
correct answer. For local PeCa Ta or T1a ther-
apy, 87.3% chose a therapeutic approach rec-
ommended by the EAU guidelines (laser therapy
17.9%; resurfacing of the glans penis 9.8%;
glansectomy i.a. partial 59.7%). No participant
opted for radiotherapy even though it is a rec-
ommended therapeutic approach. Partial
Table 2 Information on participating medical centers
Criterion n (%)





Number of university hospitals 19 (42.2%)
The department/clinic is providing 45 (100%)
Organ-sparing surgery 41 (91.1%)
Laser ablation 36 (80%)
Local radiotherapy 21 (46.7%)
Criterion n (IQR)
Median number of urologists per center 14 (10–18)
Median number of in-house patient capacity (beds) per department 39 (30–50)
Median number of patients with PeCa treated in 2017 in each urological department 5 (3–8)
This table provides detailed information on the participating departments of urology. The information was obtained by the
E-PROPS study group survey and given in total numbers and percentages in relation to the total number of participating
medical centers. Median numbers are given with the interquartile range
Adv Ther (2020) 37:4969–4980 4973
penectomy was chosen by 6.8% although it is
not indicated in this tumor stage; 5.9% declared
not to know the correct answer. For local ther-
apy of PeCa T1b, 59.1% chose a therapeutic
approach recommended by the EAU guidelines
(glansectomy—i.a. partial 59.1%; radiotherapy
0%). No participant chose radiotherapy, even
though it is a feasible choice in this tumor stage;
33.7% chose a therapeutic approach not rec-
ommended by the EAU guidelines (laser therapy
0.6%; resurfacing of the glans penis 1.3%; par-
tial penectomy 31.7%) and 7.3% declared not to
know the correct answer.
Less than half of all participants (42.4%)
decided for a correct therapeutic approach in all
tumor stages; 7.6% did not recommend any
correct treatment.
Stepwise multivariate linear regression anal-
ysis revealed that the variables ‘‘level of training
of the physician,’’ ‘‘availability of penile-sparing
surgery at the hospital,’’ ‘‘number of PeCa
patients treated at the hospital’’ and ‘‘resource-
based answering’’ are connected to the number
of guideline-conform treatment
recommendations given by the participants
(Table 6). These findings could be validated
with bootstrapping. Physicians with a higher
degree of medical training have more often
given correct treatment recommendations. The
same applies to physicians who were working in
a hospital with high numbers of PeCa patients
and/or where penile-sparing surgery is offered.
Using resources including the EAU guidelines
also lead to more correct treatment recom-
mendations. Other variables, such as ‘‘perform-
ing PeCa surgeries autonomously,’’ ‘‘knowledge
of HPV-prevalence in PeCa,’’ ‘‘location’’ and
‘‘size of the urologic department,’’ ‘‘academic
status of the hospital’’ and whether the ‘‘hospi-
tal offers radiotherapy or laser therapy’’ are not
linked to giving correct treatment
recommendations.
DISCUSSION
Keeping updated on important new findings in
diagnostics and therapy of the respective
Table 3 Translated survey questions regarding local tumor therapy in PeCa
Q1: What kind of local treatment would a patient get in your clinic if he was diagnosed with penile cancer cTis locally
restricted to the glans penis? (correct answers are highlighted in bold)
(a) Topical therapy (b) Laser therapy
(c) Resurfacing of the glans penis (d) Partial penectomy
(e) Local radiotherapy (f) I am not sure
Q2: What kind of local treatment would a patient get in your clinic if he was diagnosed with penile cancer cTa and cT1a
locally restricted to the glans penis? (correct answers are highlighted in bold)
(a) Laser therapy (b) Resurfacing of the glans penis
(c) Glansectomy (if applicable only partial) (d) Partial penectomy
(e) Local radiotherapy (f) I am not sure
Q3: What kind of local treatment would a patient get in your clinic if he was diagnosed with penile cancer cT1b locally
restricted to the glans penis? (correct answers are highlighted in bold)
(a) Laser therapy (b) Resurfacing of the glans penis
(c) Glansectomy (if applicable only partial) (d) Partial penectomy
(e) Local radiotherapy (f) I am not sure
This table provides the survey questions from the E-PROPS study group survey regarding local tumor therapy in PeCa.
They are translated from German to English but otherwise not changed. The correct answers are highlighted in bold
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disease is essential for all physicians to provide
their patients with high standard medical care.
The guidelines of international organizations,
such as the EAU are an essential tool in this
respect. Evidence-based therapy recommenda-
tions should reduce personal bias and improve
the success of treatment.
However, several studies have shown that
adherence to guidelines by physicians in all
specialties is still lacking to a significant extent.
A recent study from The Netherlands
highlighted this problem by comparing treat-
ment regimens recommended by their national
oncologic guidelines with treatment regimens
patients received for tumor therapy, showing
variances in adherence from 40 to 99%,
depending on the tumor entity [10]. However, it
is difficult to identify a single cause. Instead, the
variance in compliance shows that there must
be essential disease-specific differences. To our
knowledge, only three retrospective studies
exist so far comparing guideline
Table 4 Independent variables with potential influence on treatment decisions
Variables—information provided by the participant
Level of medical training (resident, specialist, senior physician, chief physician)
The respondent performs surgeries for penile cancer on their own
The respondent knows about the correct prevalence for HPV in penile cancer
The respondent used any source of reference (i.e., EAU guidelines) to answer the questionnaire
Variables—information provided by the participating center
Exact number of beds for inpatient care at the urological department
Exact number of doctors working at the urological department
Exact number of patients suffering from penile cancer being treated surgically in 2017 at the hospital
Academic status of the hospital (university vs. non-university)
Country the hospital is located in
The hospital provides curative intended radiotherapy for penile cancer patients
Penile-sparing surgery for penile cancer is performed at the hospital
Laser therapy for penile cancer is performed at the hospital
This table provides all 12 independent variables with a potential influence on treatment decisions. The variables were
obtained from the E-PROPS survey and are subdivided into variables that contain information about the participating
physicians and those that contain information on the participating urological department
Table 5 Therapeutic decision validity in localized PeCa
Question Number of correct responses (%)
Local Tis therapy 410 (80.4)
Local Ta or T1a therapy 448 (87.3)
Local T1b therapy 309 (59.1)
This table gives information on the number of correct answers for local tumor therapy in stages Tis, Ta, or T1a and T1b in
total numbers and percentages in relation to the total number of participants
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recommendations and actual treatment regi-
mens for local tumor treatment in PeCa
[8, 9, 11]. Compliance ranged between 66 and
74.8%. In our survey guideline adherence was
dependent on the local tumor stage. For PeCa
Tis 80.4%, Ta-T1a 87.3% and T1b 59.1% of the
participants chose a procedure that was within
the guideline recommendations. Despite great
adherence for low local tumor stage (Tis-T1a),
only 42.4% of all participants were able to
choose a correct treatment approach in all
tumor stages. Furthermore, 7.6% did not choose
any correct therapeutic approach at all. Of
course, it should be noted that the survey results
may not reflect ‘‘real-life scenarios’’. Choosing a
therapeutic approach in a survey is usually
handled with less care than if it was for a real
patient. Likewise, in daily practice, key deci-
sions on therapeutic regimens are usually made
by or are at least evaluated by an experienced
physician. Our survey however involved physi-
cians from different countries and different
hospitals, with a broad variance in experience
and medical education. This gives us a unique
opportunity to determine the main factors that
lead to higher compliance with the guidelines.
The Hospitals PeCa Caseload Predicts
Guideline Compliance
An important predictor for correct local tumor
therapy is the number of PeCa patients treated
at a hospital per year. Physicians working at a
clinic with a higher frequency of PeCa patients
suggested a guideline-based therapy more often.
Our results further support the conclusions of
previous authors who consider the centraliza-
tion of medical care as the main key for better
care of PeCa patients (1214 [12–14]). Bayles
et al. compared the surgical results and the
therapeutic success of patients at a single hos-
pital before and after it became a regional ref-
erence center for PeCa. Bundling of patients
resulted in a significantly higher rate of organ-
preserving surgery, especially in patients with
advanced local tumor stages [12]. However, it
remains questionable whether the increase in
organ-preserving interventions detected in this
study can be solely attributed to the rise in
patient frequency. The control group studied by
Bayles et al. before the introduction of central-
ized medical care consists of patients who
underwent surgery between 1969 and 1990. At
that time, it was common practice to have a
safety distance of at least 2 cm when resecting
PeCa. Only after the examined hospital became
Table 6 Stepwise multivariate linear regression-bootstrapping validation with 1000 re-samples for identification of variables
with potential influence on treatment decisions
Correct responses Regression coefficient B (95% confidence interval) p value
Constant 1.368 (1.092–1.687) 0.001
Number of patients in 2017* 0.032 (0.019–0.046) 0.001
Level of medical training** 0.356 (0.205–0.509) 0.001
Resource-based answers*** 0.419 (0.248–0.564) 0.001
Medical infrastructure**** 0.310 (0.000–0.623) 0.048
This table gives information on the results of the statistical analysis (stepwise multivariate linear regression-bootstrapping
validation with 1000 re-samples). Four variables with potential influence on treatment decisions were identified and are
listed. The regression coefficient was calculated, and the p values are given
*Surgically treated for PeCa (per hospital)
**Resident or specialist
***Use of any source of reference for answering the questionnaire (e.g. EAU guidelines)
****Penile-sparing surgery is offered at the hospital
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a regional center for PeCa were studies able to
prove that safety margins of only a few mil-
limeters result in an equally good local result,
making it the new standard of care [6]. Without
this knowledge, organ-preserving surgery could
never have been established. Thus, it is difficult
to differentiate between the contributions to
the improvement of local therapy made by the
centralization of medical care and the findings
on the surgical safety margin. In contrast to the
absolute number of PeCa patients, the size of
the clinic (assessed by the number of inpatient
beds and medical staff) had just as little influ-
ence on guideline adherence as its level of care
(primary care hospital, secondary care hospital,
maximum-care hospital) or its academic status
(university hospital: yes or no). These findings
further underline that in such a rare disease as
PeCa, regular exposure is of utmost importance
and cannot be compensated by structural
improvements alone.
Availability of Penile-Sparing Surgery
Predicts Great Guideline Compliance
In addition to the number of patients with PeCa
treated at a clinic per year, the surgical arma-
mentarium offered also has a high predictive
value. Physicians working in a hospital provid-
ing penile-sparing surgery were more likely to
adhere to the guidelines for their treatment
decisions. The availability of penile-sparing
surgery is particularly important for local tumor
stage T1b. While there are various other less
invasive therapeutic options for local tumor
stages Tis-T1a, such as laser or topical therapy,
radiotherapy is the only less invasive therapeu-
tic alternative to tumor stage T1b [2]. However,
none of the participating physicians recom-
mended local radiotherapy for tumor stages Ta-
T1b. Therefore, it is not surprising that the
possibility of being able to carry out local
radiotherapy at the same clinic did not influ-
ence guideline adherence at all. In our survey,
33.7% recommended a treatment regime for
tumor stage T1b that did not comply with the
guidelines. In the majority of cases a too radical
surgical method—in this case partial penectomy
(31.7% of 33.7%)—was chosen. In contrast,
only 1.9% chose a too superficial procedure,
laser therapy (0.6%) or resurfacing of the glans
1.3%. This is in line with the findings of Bada
et al. and Cindolo et al. who also showed that
physicians are more likely to choose a too rad-
ical rather than a too superficial surgical
approach, a problem that is aggravated in less
experienced centers [11, 15]. On a positive note,
[90% of the physicians that participated in our
survey stated that penile-sparing surgery is
common practice in their department.
The Physicians’ Skills Predict Guideline
Compliance
Not only differences between the hospitals but
also differences among the treating physicians
have a great influence on correct tumor treat-
ment. The treating physicians’ level of medical
education is an essential predictor for correct
local tumor treatment. Thus, specialists are
more likely to recommend a treatment
approach that complies with the guidelines
than residents. Curiously, this does not apply to
the physicians’ surgical skills as the ability to
perform surgery on the penis autonomously was
not a predictor for correct local tumor treat-
ment. Why the latter does not influence the
correct tumor therapy is difficult to explain,
because it must be assumed that the group of
specialists and the group of experienced sur-
geons are largely similar. However, this result
underlines the importance of clinical experi-
ence in the management of oncologic patients
in a surgical discipline like urology.
Resource-Based Answering
Nonetheless, it is not only clinical experience
but also the use of supporting materials in the
decision-making process that helps physicians
to choose the correct treatment, and this is
therefore an essential predictor for guideline
compliance; 23.3% of the participants stated
that they had used any additional source of
reference to answer the questionnaire. Which
kind of resource had been used was not speci-
fied. However, it is very likely that national or
international guidelines, or at least the
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hospitals’ standardized treatment plans, were
used to answer the questions. As this has led to
an improvement in therapy recommendations,
it may be concluded that they are easy to
understand and practical to implement. More-
over, a low level of evidence in the guidelines’
recommendations, as is the case for penile
cancer, does not deter physicians from follow-
ing them. This indicates that physicians
acknowledge that guidelines represent the best
evidence available and are willing to accept
their recommendations regardless of the sig-
nificance of the data they are based on. This
shows impressively that it is only possible to
improve patient care by proving the effective-
ness of therapy concepts with high-quality
studies. Hence, these kinds of studies are miss-
ing for penile cancer, and their initiation has to
be further promoted.
This study has several limitations. First, it
does not reflect real-life data. In clinical practice
treatment decisions are not made based on
guideline recommendations alone; they are
made depending on the state of health of the
patient, his therapy wishes and the treating
physicians’ personal experience. Of course, they
represent the best evidence available, but
‘‘guidelines are not mandates and do not pur-
port to be a legal standard of care’’ [2]. However,
due to the small number of cases, it is particu-
larly difficult to develop great expertise in
dealing with PeCa patients. The median num-
ber of patients treated for PeCa in the partici-
pating centers in 2017 was as low as 5 (IQR 3–8).
Consequently, the guidelines are of particular
importance in the management of these
patients. As we know from previous retrospec-
tive studies, the contrary position of the treat-
ing physician is one of the main reasons that
treatment regimens do not follow the guideli-
nes [8]. This in turn explains the strength of our
study. It deals exclusively with the physicians’
treatment decisions. Other confounders also
influencing treatment decisions in everyday life
are faded out. In this way, we were able to
identify four parameters that predict the
physicians’ guideline compliance for local
treatment of PeCa. It is hoped that observance
of these principles (1: treatment of patients in
high volume centers; 2: penile-sparing surgery
is offered by the treating hospital; 3: experi-
enced physicians are involved in the primary
therapy decision; 4: in case of any doubt, a
source of reference is used) in everyday life will
lead to a better rate of guideline-based therapy
recommendations and therefore will promote
the therapeutic outcome of PeCa patients,
especially for patients with a local tumor stage
cT1b, who require a less invasive therapy, such
as penile-sparing surgery, for the best possible
functional result.
CONCLUSION
Our survey-based data lead us to the conclusion
that patients with PeCa are best treated by
experienced physicians, in centers with a high
number of cases, which also offer a wide range
of local tumor therapies. In our opinion, this is
only possible in specialized centers. This in turn
leads to a repetition of the E-PROPS groups’
demand that a European or at least national
network for second opinions for PeCa patients
should be established [16, 17]. Until then, the
best way to improve patient care for PeCa is to
promote the use of auxiliary materials, such as
the EAU guidelines, as this is the easiest way to
ensure that inexperienced physicians know how
to treat PeCa, too.
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